<?xml version="1.0" encoding="UTF-8"?>
<rss xmlns:dc="http://purl.org/dc/elements/1.1/" version="2.0">
  <channel>
    <title>DSpace Собрание: Human Psychopharmacology: Clinical and Experimental provides a forum for the evaluation of clinical and experimental research on both new and established psychotropic medicines.</title>
    <link>http://hdl.handle.net/20.500.12701/2028</link>
    <description>Human Psychopharmacology: Clinical and Experimental provides a forum for the evaluation of clinical and experimental research on both new and established psychotropic medicines.</description>
    <pubDate>Fri, 03 May 2024 12:21:00 GMT</pubDate>
    <dc:date>2024-05-03T12:21:00Z</dc:date>
    <item>
      <title>Association of ANKK1 polymorphism with antipsychotic-induced hyperprolactinemia</title>
      <link>http://hdl.handle.net/20.500.12701/2029</link>
      <description>Название: Association of ANKK1 polymorphism with antipsychotic-induced hyperprolactinemia
Авторы: Fedorenko, Olga Yu.; Paderina, Diana Z.; Loonen, Anton J. M.; Pozhidaev, Ivan V.; Boiko, Anastasiia S.; Kornetova, Elena G.; Bokhan, Nikolay A.; Wilffert, Bob; Ivanova, Svetlana A.
Краткий осмотр (реферат): Schizophrenia is a severe highly heritable mental disorder. Genetic polymorphisms of dopaminergic pathways are related to pathogenesis of drug response. Hyperprolactinemia (HPRL), a common adverse effect of antipsychotics, is attributed to blockade of dopamine D2 receptors. Ankyrin Repeat and Kinase Domain containing 1 (ANKK1) gene is closely related to Dopamine Receptor D2 type (DRD2) gene functioning. We examined whether the functional polymorphism rs2734849 in the ANKK1 gene is associated with antipsychotic-induced HPRL.</description>
      <pubDate>Fri, 08 May 2020 00:00:00 GMT</pubDate>
      <guid isPermaLink="false">http://hdl.handle.net/20.500.12701/2029</guid>
      <dc:date>2020-05-08T00:00:00Z</dc:date>
    </item>
  </channel>
</rss>

